Coroflex® ISAR NEO PMCF Study

Inclusion Criteria:

Coroflex® ISAR NEO is intended to be used for

• Patients must be at least 18 years of age AND

• The patient must fulfill the standard recommendations for Percutaneous CoronaryIntervention (PCI) based on the last European Society of Cardiology (ESC)recommendations within his/ her regular treatment or that the use of the product hasalready been decided within the regular planning of the patient's treatment AND

• Patients with Novo lesion length 2-4 mm AND

• Informed consent signed

Exclusion Criteria:

• Patients with express refusal by the patient to participate in the study.

• Patients pregnant women and lactating women.

• Patients with acute coronary syndrome (ACS) in a situation of cardiogenic shock (Killip 4).

• Patients in whom anti-platelet and/or anti-coagulation therapy is contraindicated

• Patients with lesions, that possibly can not be treated successfully withPercutaneous transluminal Coronary Angioplasty (PTCA) or stent implantation

• Patients with known sensitivity to Sirolimus, the carrier Probucol, the proceduralco-medication or the alloying component of the stent

• Patients with known sensitivity to contrast agents who cannot be premedicated.

• Patients with contraindications or hypersensitivity to sirolimus

• Patients with a life expectancy of less than 2 years

• Patients included in other clinical trials